Company intelligence / Profile preview

Wuhan Ammunition Life-tech

Wuhan, Hubei Sheng, Chinawaltglobal.com ↗

Ownership: Private
Development stage: Commercial

Overview

Wuhan Ammunition Life-tech has developed a new generation of non-invasive cancer detection products using methylation liquid biopsy technology. Their tests have shown high accuracy for early detection of various cancers including endometrial and urothelial carcinomas. Clinical studies support the efficacy of their biomarker panels for non-invasive diagnosis.

Therapeutic areas: Oncology
Modalities: Diagnostic testLiquid biopsy (methylation-based)
Industry: Molecular Diagnostics

Drug pipeline

6 assets

IColocomf

Commercial

Indications: Colorectal cancer

5 more assets in the full pipeline.

Request access →

Partnerships

Roche Diagnostics – strategic cooperation agreement signed in August 2022 to advance diagnostic solutions

Beyond the preview

Go deeper on Wuhan Ammunition Life-tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Ammunition Life-tech.

Explore the full profile